Valuation : Evotec SE

Market Cap 571M 663M 537M 491M 918M 62.64B 920M 6.35B 2.46B 32.14B 2.49B 2.44B 104B P/E 2026 *
-2.74x
P/E 2027 * -7.47x
Enterprise Value 714M 829M 672M 613M 1.15B 78.32B 1.15B 7.94B 3.08B 40.18B 3.11B 3.05B 129B EV / Sales 2026 *
1.19x
EV / Sales 2027 * 1.01x
Free-Float
89.91%
Yield 2026 *
-
Yield 2027 * -
1 day-41.85%
1 month-41.85%
3 months-41.85%
6 months-37.35%
Current year-51.43%
1 month 3.89
Extreme 3.8905
3.89
Current year 3.89
Extreme 3.8905
6.69
1 year 3.89
Extreme 3.8905
8.36
3 years 3.89
Extreme 3.8905
24.61
5 years 3.89
Extreme 3.8905
52.21
10 years 3.89
Extreme 3.8905
52.21
Manager TitleAgeSince
Chief Executive Officer 55 01/07/2024
Director of Finance/CFO - 01/05/2026
Chief Operating Officer - 01/05/2026
Director TitleAgeSince
Director/Board Member 58 19/06/2019
Director/Board Member 64 01/06/2021
Director/Board Member 59 10/06/2024
Change 5-day change 1-year change 3-year change Capi.($)
-41.85%-.--% - - 663M
-2.54%-2.84%-1.77%+14.72% 48.93B
-0.40%+1.03%+418.57%+523.39% 45.01B
-1.42%+2.30%+42.67%+21.22% 44.07B
-1.22%-2.31%+4.82%+74.90% 40.73B
+0.53%-1.36%+16.87%+47.12% 33.52B
-0.21%+9.14% - - 17.77B
-0.35%-1.56%+21.42%+123.04% 16.5B
-1.01%+0.50%+13.91%+31.45% 14.67B
-1.65%-1.03%+75.93%+41.22% 13.77B
Average -5.01%+0.53%+74.05%+109.63% 30.55B
Weighted average by Cap. -1.13%+0.11%+89.42%+127.93%

Financials

2026 *2027 *
Net sales 601M 698M 565M 516M 966M 65.93B 969M 6.68B 2.59B 33.83B 2.62B 2.56B 109B 724M 841M 681M 622M 1.16B 79.45B 1.17B 8.05B 3.12B 40.76B 3.16B 3.09B 131B
Net income -202M -235M -190M -174M -325M -22.16B -326M -2.25B -871M -11.37B -881M -862M -36.63B -48.25M -56.07M -45.4M -41.47M -77.58M -5.29B -77.79M -536M -208M -2.72B -211M -206M -8.75B
Net Debt 143M 166M 134M 123M 230M 15.67B 230M 1.59B 616M 8.04B 623M 610M 25.91B 162M 188M 153M 139M 261M 17.79B 261M 1.8B 700M 9.13B 708M 692M 29.41B
Logo Evotec SE
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Employees
4,461
Trader
Investor
Global
Quality
ESG MSCI
AAA
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
8
Last Close Price
3.212EUR
Average target price
4.586EUR
Spread / Average Target
+42.77%

Quarterly revenue - Rate of surprise